References

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

10.1038/s41575-020-0310-z · 2020 · External reference

Anatomical, histomorphological and molecular classification of cholangiocarcinoma

10.1111/liv.14093 · 2019 · External reference

Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States

10.1093/jnci/djj234 · 2006 · External reference

Descriptive epidemiology of cholangiocarcinoma in Italy

10.1016/j.dld.2009.10.009 · 2010 · External reference

Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia

10.3748/wjg.v18.i5.458 · 2012 · External reference

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

10.1038/nrgastro.2016.51 · 2016 · External reference

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

10.1053/j.gastro.2011.12.005 · 2012 · External reference

Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features

10.1038/modpathol.2013.241 · 2014 · External reference

Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma

10.1016/j.hpb.2018.07.021 · 2019 · External reference

Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities

10.1016/j.humpath.2022.06.001 · 2023 · External reference

FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH

10.1007/s00428-025-04067-9 · 2025 · External reference

Genomic spectra of biliary tract cancer

10.1038/ng.3375 · 2015 · External reference

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma

10.1158/2159-8290.cd-17-0368 · 2017 · External reference

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

10.1158/1078-0432.ccr-18-0078 · 2018 · External reference

Advances and challenges in targeting FGFR signalling in cancer

10.1038/nrc.2017.8 · 2017 · External reference

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

10.1158/1078-0432.ccr-14-3212 · 2016 · External reference

Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features

10.1016/j.dld.2024.04.025 · 2024 · External reference

Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

10.1158/2159-8290.cd-20-0766 · 2021 · External reference

Molecular targeted therapies: Ready for "prime time" in biliary tract cancer

10.1016/j.jhep.2020.03.007 · 2020 · External reference

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

10.1002/hep.26890 · 2014 · External reference

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas

10.1038/s41419-021-03548-4 · 2021 · External reference

Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement

10.1016/j.tranon.2021.101168 · 2021 · External reference

Precision oncology for intrahepatic cholangiocarcinoma in clinical practice

10.1038/s41416-022-01932-1 · 2022 · External reference

Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

2023 · External reference

Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype

10.1200/po.17.00080 · 2018 · External reference

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

10.1038/s41416-022-01908-1 · 2022 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

OncoKB: A Precision Oncology Knowledge Base

2017 · External reference

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

10.1200/jop.2016.018929 · 2017 · External reference

Role of the fibroblast growth factor receptor axis in cholangiocarcinoma

10.1111/jgh.12916 · 2015 · External reference

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention

10.3390/ijms21186856 · 2020 · External reference

Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database

10.1186/s12876-016-0527-z · 2016 · External reference

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing

10.1634/theoncologist.2013-0352 · 2014 · External reference

FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma

10.1093/oncolo/oyae170 · 2024 · External reference

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

10.1007/s11523-022-00906-w · 2022 · External reference

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

10.1097/mog.0000000000000171 · 2015 · External reference

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion

10.3389/fonc.2025.1527484 · 2025 · External reference

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

10.1158/2159-8290.cd-21-0697 · 2022 · External reference

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

10.1016/j.annonc.2022.02.001 · 2022 · External reference

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy

10.1158/2159-8290.cd-24-0417 · 2025 · External reference

Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

10.1158/1538-7445.am2021-935 · 2021 · External reference

Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma

10.1097/pas.0000000000000670 · 2016 · External reference

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

10.1016/j.jhep.2022.11.030 · 2023 · External reference

Identification of targetable FGFR gene fusions in diverse cancers

10.1158/2159-8290.cd-13-0050 · 2013 · External reference

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

10.1038/ncomms7087 · 2015 · External reference

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

10.1038/sj.onc.1210529 · 2007 · External reference

p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice

10.1172/jci62644 · 2012 · External reference

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

10.1158/2159-8290.cd-20-1669 · 2021 · External reference

Activation of FGF receptors by mutations in the transmembrane domain

10.1038/sj.onc.1200983 · 1997 · External reference

Receptor tyrosine kinases activate canonical WNT/beta-catenin signaling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation

10.1371/journal.pone.0035826 · 2012 · External reference

FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?

10.3390/cells11233929 · 2022 · External reference

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma

10.1016/j.phrs.2025.107968 · 2025 · External reference

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

10.1158/2159-8290.cd-16-1000 · 2017 · External reference

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology

10.6004/jnccn.2025.0042 · 2025 · External reference

Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis

10.1111/liv.15984 · 2024 · External reference

Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection

10.1016/j.hpb.2022.05.1341 · 2022 · External reference

CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma

10.1038/s41598-017-17175-7 · 2017 · External reference

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma

10.3389/fgene.2022.844800 · 2022 · External reference

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis

2023 · External reference

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

10.1016/j.esmoop.2024.103488 · 2024 · External reference